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To the Editor: Meyer et al. reported important results of a large, multicenter trial evaluating the effect of fibrinolysis in patients with intermediaterisk pulmonary embolism. The authors evaluated interactions (i.e., different treatment effects in subgroups of the population) on a relative scale using logistic regression and found a trend toward a greater risk of major extracranial bleeding among patients older than 75 years of age (odds ratio, 20.38, vs. 2.80 among patients 75 years of age or younger; P = 0.09).
If the interaction had been assessed on an absolute scale, very different conclusions regarding treatment safety in elderly patients would have been drawn. Indeed, among patients 75 years of age or younger, 14 of 344 patients in the fibrinolysis group (4.1%) and 5 of 335 patients in the placebo group (1.5%) had major bleeding, resulting in an absolute risk difference of 2.6 percentage points (95% confidence interval [CI], 0.1 to 5.0). In contrast, among patients older than 75 years of age, 18 of 162 patients in the fibrinolysis group (11.1%) and 1 of 164 patients in the placebo group (0.6%) had major bleeding, resulting in an absolute risk difference of 10.5 percentage points (95% CI, 5.5 to 15.5). decompensation with the use of fibrinolytic therapy in patients with intermediate-risk pulmonary embolism, yet with an increase in hemorrhagic events. Significant variability among study participants in response to plasminogen activators has been reported in healthy volunteers. 1 Furthermore, this variability can be more pronounced in older patients 2 and those with inflammatory conditions, given variations in levels of endogenous inhibitors of fibrinolysis -such as plasminogen activator inhibitor type 1 (PAI-1), thrombin-activatable fibrinolysis inhibitor, antiplasmin, and α 2 -macroglobulin -as well as diurnal fluctuation of PAI-1. 3 We have recently found profound differences in ex vivo tissue plasminogen activator-induced fibrinolysis among severely injured patients, ranging from hypersensitivity (hyperfibrinolysis) to complete resistance (fibrinolysis shutdown). 4 Thromboelastography, which measures changes in the viscoelasticity of whole blood, has been validated clinically as a tool to quantify hyperfibrinolysis in trauma patients and to guide antifibrinolytic therapy. 5 Conversely, a role could exist for viscoelastic assays to guide fibrinolytic therapy by permitting the adjustment of the drug dose on the basis of the patient's fibrinolytic response ex vivo. Such goaldirected therapies with the use of plasminogen activators have yet to emerge and could reduce hemorrhagic complications while ensuring effectiveness, thus allowing for safe implementation of emerging thrombolytic therapies. 
To the Editor: Although we laud the publication of the results of the PEITHO trial, in which the investigators conclude that prompt fibrinolysis can reduce the risk of hemodynamic decompensation or death among normotensive patients who have pulmonary embolism with right ventricular dysfunction or myocardial injury, we wish to raise the following concerns. The absence of a core laboratory for assessment of imaging of right ventricular dysfunction raises the possibility of a wide variability in the interpretation of images of a cardiac structure that is particularly difficult to evaluate by means of transthoracic echocardiography. On multidetector computed tomographic (CT) pulmonary angiography, the exact image to be chosen for the right ventricular:left ventricular diameter ratio can be quite subjective. Reconstructed CT four-chamber views are also superior to those from axial views. 1
Because thrombolysis is associated with hemorrhagic complications, the use of the simplified Pulmonary Embolism Severity Index (PESI) score can identify patients at very low risk. regarding the development of chronic thromboembolic pulmonary hypertension after submassive pulmonary embolism. The overall incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism is 2 to 4% 1 ; however, no one has rigorously studied its incidence after submassive pulmonary embolism. Kline et al. 2 and Fasullo et al. 3 found that patients who received up-front thrombolysis (as the initial therapeutic approach) had reduced right ventricular systolic pressures (<40 mm Hg) and improved function. We believe that uncertainties still exist regarding the potential benefit of thrombolysis in this particular subgroup of patients with objective quantitative echocardiographic evidence of persistent pulmonary hypertension. It would be helpful for clinicians if the authors would consider analyzing the subgroup of patients with persistent pulmonary hypertension, addressing the associated end point of chronic thromboembolic pulmonary hypertension, which confers higher mortality among survivors. We believe that by addressing the echocardiographic predictors of chronic thromboembolic pulmonary hypertension and by characterizing more accurately this controversial but intriguing phenotype of patients, clinicians may better understand who will benefit most from thrombolysis. 
To the Editor: In his editorial about the PEITHO trial, Elliott 1 notes that half-dose fibrinolysis has been studied in the management of myocardial infarction but not pulmonary embolism. 2 We would like to bring the Moderate Pulmonary Embolism Treated with Thrombolysis (MOPETT) trial 3 to the attention of Journal readers.
The MOPETT trial used a definition of moderate-risk pulmonary embolism that was similar to that used in the PEITHO study and randomly assigned patients to alteplase infusion or placebo, in addition to fractionated heparin or subcutaneous enoxaparin. However, unlike the PEITHO trial, the MOPETT trial halved the conventional weight-based dosing for the treatment of massive pulmonary embolism. Among the 121 patients who underwent randomization, mortality at index hospitalization was similar in the thrombolysis and control groups (1.6% and 5.0%, respectively), and no bleeding complications were observed in either group. This trial was also positive for its primary outcome of decreased cardiovascular morbidity from pulmonary hypertension at long-term follow-up. Despite a small sample and the need for further validation, the MOPETT trial suggests that half-dose thrombolysis may indeed be a promising, lower-risk therapy for patients with intermediate-risk moderate pulmonary embolism. Rory J. Spiegel, M.D.
of low-molecular-weight heparin and randomiza
